0001104659-24-001628.txt : 20240105 0001104659-24-001628.hdr.sgml : 20240105 20240105080819 ACCESSION NUMBER: 0001104659-24-001628 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Twist Bioscience Corp CENTRAL INDEX KEY: 0001581280 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462058888 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38720 FILM NUMBER: 24514480 BUSINESS ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 800-719-0671 MAIL ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 tm2333797d1_8k.htm FORM 8-K
false 0001581280 0001581280 2024-01-05 2024-01-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

January 5, 2024

 

 

Twist Bioscience Corporation

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-38720   46-2058888

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I. R. S. Employer

Identification No.)

 

681 Gateway Boulevard

South San Francisco, CA 94080

(Address of principal executive offices, including ZIP code)

 

(800) 719-0671

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock   TWST   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 5, 2024, Twist Bioscience Corporation (the “Company”) announced the appointment of Adam Laponis as the Company’s Chief Financial Officer and principal financial officer, effective January 8, 2024.

 

Mr. Laponis, age 47, previously served as the Chief Financial Officer of Eargo, Inc., a hearing aid manufacturing company, from June 2019 to January 2024. From November 2018 to March 2019, Mr. Laponis served as Vice President of Financial Planning and Analysis for Tesla, an automotive and energy company, where he previously served as Senior Director of Finance from April 2017 to November 2018. Prior to that, he served as the Vice President and Chief Financial Officer of Cardiovascular Care of Cardinal Health, a healthcare services and products company, from October 2015 to April 2017. Prior to that, he served in various financial roles at Johnson & Johnson, a healthcare company, from August 2004 to October 2015. Mr. Laponis holds a B.S. in Chemical Engineering from the University of California, Berkeley and an M.B.A. from the University of Southern California.

 

In connection with Mr. Laponis’ appointment as Chief Financial Officer, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Laponis. Under the terms of the Employment Agreement, Mr. Laponis will receive an annual base salary of $450,000; a signing bonus of $195,000, subject to repayment of the full gross amount if, prior to the one-year anniversary of the start date of employment, Mr. Laponis is terminated by the Company for Cause (as defined in the Employment Agreement) or voluntarily terminates his employment with the Company without Good Reason (as defined in the Employment Agreement); annual incentive compensation for 2024 with a target level equal to 55% of his annual base salary; and a new hire equity grant consisting of (a) 50,000 restricted stock units (“RSUs”), which will vest quarterly over four years with a one-year cliff, and (b) 70,000 shares subject to the Company’s executive compensation programs, of which (i) 25,000 RSUs will vest quarterly over four years with no cliff, (ii) 25,000 performance stock units (“PSUs”) will vest based on achievement against the metrics established in connection with the Company’s fiscal year 2024 long-term incentive program, and (iii) 20,000 PSUs will vest based on achievement against the metrics established in connection with the Company’s fiscal year 2024 cash balance measurement program. In addition, the Employment Agreement provides for certain payments and benefits in the event of termination of Mr. Laponis’ employment under specific circumstances including, but not limited to, a change in control event. The foregoing description of the Employment Agreement is a summary and is qualified in its entirety by reference to the text of the Employment Agreement, which will be filed as an exhibit to the Company’s Form 10-Q for the fiscal quarter ending December 31, 2023 and is incorporated herein by reference. There are no family relationships between Mr. Laponis and any of the Company’s directors or executive officers, and Mr. Laponis has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

As previously reported by the Company in its Form 8-K filed on August 4, 2023 (the “Prior 8-K”), upon commencement of employment by Mr. Laponis, James Thorburn will no longer serve as the Company’s Chief Financial Officer. For more information on Mr. Thorburn’s role with the Company, see the Prior 8-K.

 

 

 

Item 7.01Regulation FD.

 

On January 5, 2024, the Company issued a press release announcing Mr. Laponis’ appointment as Chief Financial Officer, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information included in this Item 7.01 and in the press release attached as Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall any such information or exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such document.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit No.   Description
99.1   Press release dated January 5, 2024
     
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 5, 2024 Twist Bioscience Corporation
   
  /s/ Judy Yan
  Judy Yan
  Assistant General Counsel and Assistant Secretary

 

 

 EX-99.1 2 tm2333797d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

 

SOUTH SAN FRANCISCO, – January 5, 2024 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth.

 

“Adam’s deep financial acumen and strategic planning expertise across diverse businesses make him an ideal fit for our next phase of growth,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “His wide-ranging experience within large pharma and their business units, automobile manufacturers and start-up organizations will provide valuable insights as we scale the business, remaining laser focused on driving toward profitability and expanding gross margin while serving our customers and enabling them to conduct breakthrough research.”

 

“Throughout my career I have been drawn to mission-driven companies, and I’m particularly excited to join Twist at this pivotal time as the company is moving toward cash flow breakeven,” said Mr. Laponis. “Twist’s ability to manufacture DNA at an unprecedented scale and speed is truly enabling positive developments in health, food security and sustainability. I look forward to working with the talented and experienced team and I’m committed to using my expertise and skillset to drive value for all of our stakeholders.”

 

Mr. Laponis joins Twist from Eargo, Inc., where he served as chief financial officer, responsible for finance, accounting, investor relations, business operations, internal audit and information technology. During his tenure at Eargo, revenue increased more than 300% over the course of two years. Prior to Eargo, Mr. Laponis was vice president, worldwide financial planning and analysis and business operations at Tesla, Inc. where he was responsible for worldwide pricing, forecasting, capital planning, development of internal controls, and optimization of business operations. Previously, Mr. Laponis served as vice president, finance and chief financial officer, cardiovascular care at Cardinal Health as the finance leader for the worldwide Cordis Cardiovascular business. He held a series of roles of increasing responsibility at Johnson & Johnson, where he led the divestiture of Cordis to Cardinal Health. He held additional positions within Johnson & Johnson including controller of the diabetes franchise, manager of supply chain and quality finance and customer service finance. Mr. Laponis holds an MBA from the University of Southern California, Marshall School of Business and a B.S. in chemical engineering from the University of California at Berkeley.

 

 

 

About Twist Bioscience Corporation

 

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

 

Follow us on Twitter | Facebook | LinkedIn | YouTube

 

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Twist Bioscience’s future growth and expansion, and ability to achieve profitability and increase gross margin. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 

 

CONTACTS:

 

For Investors:

 

Angela Bitting
SVP, Corporate Affairs
925-202-6211

abitting@twistbioscience.com

 

For Media:

 

Amanda Houlihan
Communications Generalist
774-265-5334

ahoulihan@twistbioscience.com

 

###

 

 

 EX-101.SCH 3 twst-20240105.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 twst-20240105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 twst-20240105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2333797d1_ex99-1img001.jpg GRAPHIC begin 644 tm2333797d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 05, 2024
Entity File Number 001-38720
Entity Registrant Name Twist Bioscience Corporation
Entity Central Index Key 0001581280
Entity Tax Identification Number 46-2058888
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 681 Gateway Boulevard
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 800
Local Phone Number 719-0671
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TWST
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2333797d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001581280 2024-01-05 2024-01-05 iso4217:USD shares iso4217:USD shares false 0001581280 8-K 2024-01-05 Twist Bioscience Corporation DE 001-38720 46-2058888 681 Gateway Boulevard South San Francisco CA 94080 800 719-0671 false false false false Common Stock TWST NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( E!)5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " )02588AE5 ^\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:2=(J'KBV-/"H(#Q;>0W+9@TX3DI-VW-ZU;A^@'\#%W__SN M=W"-#E+[B,_1!XQD,=V,KNN3U&'-CD1! B1]1*=2F1-];NY]=(KR,QX@*/VA M#@@5YW?@D)11I& "%F$ALK8Q6NJ(BGP\XXU>\.$S=C/,:, .'?:40)0"6#M- M#*>Q:^ *F&"$T:7O IJ%.%?_Q,X=8.?DF.R2&H:A'.HYEW<0\/;T^#*O6]@^ MD>HUYE_)2CH%7+/+Y-?Z8;/;LK;BU:K@HN"W.U%+?B_%ZGUR_>%W%7;>V+W] MQ\87P;:!7W?1?@%02P,$% @ "4$E6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" )0258IQCADCT$ !V$ & 'AL+W=OFT,TEL.3PE!68(2:[IW>5H3)N9=OI"V (TL26?)(?P M[;LRQ*9W9LV4%V#9WK]_VEWO2@PW2K^8->>6O&6I-"-O;6U^[?LF7O.,F0N5 MG[&A/3&P_+<3(^'JK"ID'RFB2FRC.GM M#4_59N11[_W$DUBMK3OACX5A5(O;O"0C+S $?&4Q]9),/AYY5.>IDX).+[N1;WJF<[P M\/A=_;Z2?B2%:E]4IM?^7Y"7:<7J]24WV2SN[?3 M\4A<&*NRO3$09$+N?MG;WA$'!N'5$8-P;Q"6W+L'E92WS++Q4*L-T>YN4',' MY51+:X 3TD4ELAJN"K"SXZEZY7KH6Y!R)_QX;W:S,PN/F/W&Y 4)NF8^OA6Q07DHB7S;YHS9EP+E9 [F1!(OD:_X$IE&I5YU)9(O8JMARK>22OL MEMR+E)/'(ELT)S>N$03T_'+0#P.$IU_Q]$_A>>(KX5(;G/;(LD9/X3KS#=B3 M&Z%,++B,.9DJG2O-7&E#, <5YN 4S"E$5;.4/,B$OY&/?-L$BBL%X+WN@(8# MS'M7%=;5*5AS]D8>$F 32Q&74T9BBRMV>N=AT!W !\&C05T]@U, 'V1!J(T!*D AX)?5=(8\Q;UVSL,\J#$TU,@)TD"A=&7C<11<8!"@('6;H'B-_Z1B\,ELK236)UI$ M^O3J/.CU*494-PJ*5_AG+:SE$AR3987J;\C>S"F +(VP!;95L"Z!X1XP9X+"RLBM20T_&GQ,XEX7$"^-?;W%B67 MG]" (ZOB%PSM8.F/E^BY9HE+L6B;+51C@K4)/$=SC*0NZB%>@-^]0N[>XC63 M*WYTL=8B]#B);B>_8TQU-0]/JN9W&=K?)W0VLRLN-Y4)9V*:6AVO.(-_=#7!]J91]'[B] M:O57P_A?4$L#!!0 ( E!)5B?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT M7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z// MEI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC M**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QK MRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C1 M6/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_ M-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+ M_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5 MUOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO4 M9X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM M\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/ MFD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( E!)5B7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://twistbioscience.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2333797d1_8k.htm twst-20240105.xsd twst-20240105_lab.xml twst-20240105_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333797d1_8k.htm": { "nsprefix": "TWST", "nsuri": "http://twistbioscience.com/20240105", "dts": { "inline": { "local": [ "tm2333797d1_8k.htm" ] }, "schema": { "local": [ "twst-20240105.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "twst-20240105_lab.xml" ] }, "presentationLink": { "local": [ "twst-20240105_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://twistbioscience.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333797d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333797d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://twistbioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-001628-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-001628-xbrl.zip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